NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

It is an ester-derived prodrug that is converted in vivo by serum and tissue esterases to tenofovir, an acyclic nucleoside phosphonate (nucleotide) that inhibits HIV reverse transcriptase.

The COVID-19 vaccine confers protection against the development of post-COVID-19 conditions, particularly during the Delta and Omicron eras.

This protocol was adapted from “Stage 1: Synthesis of first strand cDNA catalyzed by reverse transcriptase” and “Stage 2: Second strand synthesis,” in Molecular Cloning: A Laboratory ...

Chitosan, a naturally occurring polysaccharide derived from chitin, has demonstrated significant potential as an antiviral ...

Breakthrough Therapy designation Doravirine/islatravir (Merck) Combination of a non-nucleoside reverse transcriptase inhibitor and a nucleoside reverse transcriptase translocation inhibitor ...

Reverse Transcriptase-quantitative PCRs (RT-qPCRs) are reliable disease diagnostic assays but are constrained by the use of expensive equipment and reagents, limiting their utility in resource ...

The new data – presented at the IDWeek congress yesterday – found that the pairing of MSD's experimental nucleoside reverse transcriptase translocation inhibitor islatravir with Gilead's ...

Pseudoscience has recently re-emerged in the U.S. While much of it concerns vaccines, an "oldie" is again making the rounds: ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

On Friday, February 7, a hearing took place in the Montana state legislature on a bill that would ban the use of mRNA ...